Recommendation of the President – Kayfanda (odevixibat)
On 23 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 187/2025 on the reimbursement of the medicinal product Kayfanda (odevixibat) under the B.175 drug program “Treatment of patients with Alagille syndrome (ICD-10: Q44.7)”